New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
06:55 EDTCMRXChimerix reports Q2 EPS (39c), consensus (44c)
Reports Q2 revenue $919K, consensus $730K
News For CMRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
06:56 EDTCMRXChimerix shares continue to trade near cash, says Citi
Citi analyst Yigal Nochomovitz points out that Chimerix continues to trade near the company's cash position of around $7 per share. In a research note titled "Don't Throw the Baby (Brincidofovir in Kidney Transplant) Out With the Bathwater (SUPPRESS Blow-Up)," Nochomovitz says the Street has left brincidofovir "for dead" following the failed Phase 3 trial in bone marrow transplant. The drug, however, is still in Phase 3 testing for kidney transplant, the analyst tells investors. He sees potential for the Chimerix story to turn around as the kidney transplant opportunity comes into focus. Nochomovitz keeps a Buy rating on the name with a $19 price target.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use